Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01596881 · ClinicalTrials.gov registry record

Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis

A clinical trial, sponsored by Oregon Health and Science University.

Completed
Registry status
101
Enrollment target

NCT01596881 is a clinical trial that has completed, run by Oregon Health and Science University. The registered enrollment target is 101 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01596881 has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
101 participants
Enrollment target

Study Summary

Recent studies have shown that people with multiple sclerosis (MS) who also have diseases related to vascular health such as high cholesterol, high blood pressure, diabetes, cardiovascular disease, and others, may end up more disabled than people with MS who don't have those diseases. This has led to a growing interest in the role of vascular diseases in MS since they may provide another avenue of MS treatment. Some also think that vascular disease may even be a cause of MS. The back of the eye, the retina, is well-suited to studying vascular diseases as blood vessels can be seen even on routine examination of the eye by eye doctors. These specialists are used to seeing changes in retinal blood vessels due to diseases known to affect the eyes such as glaucoma and diabetes. Sophisticated techniques for examining the retina allow for not only visualization of blood vessels, but the rate of blood flow through the blood vessels as well. These blood flow changes are thought to come before changes in what the blood vessels look like, and so may be able to detect problems even earlier than routine examination of the retina by eye doctors. Retinal blood flow has never been carefully studied in MS. Given that MS affects the retina due to the late effects of inflammation of the optic nerve, or optic neuritis, the investigators expect to see altered blood flow in the retinal blood vessels of people with MS compared to healthy control subjects. If so, the investigators can then use retinal blood flow as a way to measure therapies that target vascular diseases in the MS population and determine if those therapies can alter the course of disease.

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2012-04
Est. Completion 2017-02-08

What the Registry Record Tells You About NCT01596881

The ClinicalTrials.gov registry entry for NCT01596881 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01596881 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01596881 about?

NCT01596881 is a clinical study titled "Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis". Recent studies have shown that people with multiple sclerosis (MS) who also have diseases related to vascular health such as high cholesterol, high blood pressure, diabetes, cardiovascular disease, and others, may end up more disabled than people with MS who don't have those diseases. This has led t...

What is the current status of trial NCT01596881?

This trial is currently completed. The enrollment target is 101 participants. The study started on 2012-04. Estimated completion is 2017-02-08.

Who is sponsoring clinical trial NCT01596881?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.